Abstract
In this article the authors provide insight into the basis for price setting of medicines, the increasing pharmaceutical budgets in the past decades, and the measures governments and insures have taken to curb rising pharmaceutical costs. Four reasons are out lined for the fact that medicines are by some considered expensivey: 1) there are fundamental differences between medicines and other consumer products; 2) medicines are technology requiring an inordinate amount of research and development; 3) medicines are developed, manufactured, and distributed according to strict regulatory requirements; 4) medicines are most often selected by a physician for a specific patient and reimbursed in whole or in party by a third-party insurer or the state. Pharmaceuticals mean share of GDP has been 1.2% in OECD countries in recent decades. Pharmaceuticals accounted for 15.4% of total health expenditure, with public spending about half of this amount. Since 1970, the average share of GDP for pharmaceuticals in most countries has increased 1.5% more per year than GDP growth. Four types of strategies to curb rising Pharmaceuticals costs are described and a taxonomy of strategies provided These are:1)price and profit controls; 2) reimbursement system charges; 3) other fiscal measures; 4) quality measures. Pharmaceuticals policy has suffered from the pervasive misunderstanding that drugs are like any other commodity; resulting in policy makers viewing pharmaceuticals expenditures without thinking about drugs in their proper content of health care. The authors conclude by advocating a balanced approach to policymaking in a environment of rising pharmaceuticals costs.
Similar content being viewed by others
References
AB Almarsdòttir JM Traulsen (2005) ArticleTitleRational use of medicines - an important issue in pharmaceutical policy Pharm World Sci 27 IssueID2 76–80 Occurrence Handle10.1007/s11096-005-3303-7 Occurrence Handle15999915
InstitutionalAuthorNameOffice of Technology Assessment (1980) Implication of Cost Effectiveness Analysis of Medical Technology Government Printing Office Washington, DC
JA DiMasi RW Hansen HG Grabowski (2003) ArticleTitleThe price of innovation: new estimates of drug development costs J Health Econ 22 151–85 Occurrence Handle10.1016/S0167-6296(02)00126-1 Occurrence Handle12606142
UE Reinhardt PS Hussey GF Anderson (2004) ArticleTitleU.S. health care spending in an international context – Why is U.S. spending so high, and can we afford it? Health Affair 23 IssueID3 10–25 Occurrence Handle10.1377/hlthaff.23.3.10
Strunk BC, Ginsburg PB. Tracking Health Care Costs: Trends Turn Downward in 2003. Health Affairs 2004; Suppl Web Exclusives: W4-354–62
Jacobzone S. Pharmaceutical policies in OECD countries: reconciling social and industrial goals. Labour market and social policy – occasional papers No. 40. Paris: OECD Directorate for Education, Employment, Labour and Social Affairs, 2000
C Møldrup (2004) ArticleTitleThe use of the terms ‘lifestyle medicines’ or ‘lifestyle drugs’ Pharm World Sci 26 193–6 Occurrence Handle10.1023/B:PHAR.0000035917.09650.1c Occurrence Handle15446774
CD Mullins J Wang FB Palumbo B Stuart (2001) ArticleTitleThe impact of pipeline drugs on drug spending growth Health Affair 20 IssueID5 210–5 Occurrence Handle10.1377/hlthaff.20.5.210
Róbertsson R. Division of Pharmaceutical Costs in Iceland During 1999–2003 – What is the Influence of Pipeline Drugs? Masters thesis. Reykjavík: University of Iceland, Faculty of Pharmacy, 2004
UG Gerdtham M Johannesson B Gunnarsson M Marcusson F Henriksson (1998) ArticleTitleThe effect of changes in treatment patterns on drug expenditure Pharmacoeconomics 13 IssueID1 Pt 2 127–134 Occurrence Handle10176147
AH Rietveld FM Haaijer-Ruskamp (2003) Policy options for cost containment of pharmaceuticals MNG Dukes FM Haaijer-Ruskamp CP Joncheere Particlede AH Rietveld (Eds) Drugs and Money – Prices, affordability and cost containment. IOS Press Amsterdam 29–54
AB Almarsdóttir A Grímsson I. Björnsdóttir (2003) ArticleTitleDesign and implementation of pharmaceutical policy in Iceland – the need for evaluation and understanding of the “black box” J Pharm Finance Econ Policy 12 IssueID1 1–21 Occurrence Handle10.1300/J371v12n01_01
WHO 2000. WHO, Technical Report Series 895, The Use of Essential Drugs, Geneva, 2000
JM Traulsen BO Klinke (2004) ArticleTitleUsing health technology assessment to put pharmaceutical care on the political agenda Pharm World Sci 26 IssueID2 61–3 Occurrence Handle10.1023/B:PHAR.0000018608.09295.fe Occurrence Handle15085938
Anell A, Jendtveg S, Nordling S. Prescribing and cost containment – What can Sweden learn from England, Germany and Holland? [in Swedish]. IHE -report. Lund: The Swedish Institute for Health Economics (IHE), 1999
HL Lipton KS Duke (2003) Experiences with pharmacy benefit management programmes in the USA MNG Dukes FM Haaijer-Ruskamp CP Joncheere Particlede AH Rietveld (Eds) Drugs and Money – Prices, affordability and cost containment IOS Press Amsterdam 111–8
SB Soumerai J Avorn (1990) ArticleTitlePrinciples of educational outreach (‘academic detailing’) to improve clinical decision making JAMA 63 IssueID4 549–56 Occurrence Handle10.1001/jama.263.4.549
A Nissen (2000) Academic detailing – and other methods for quality development of drug prescribing [in Danish] Danish Medicines Agency – Institute for Rational Pharmacotherapy Copenhagen
S. Macgregor (2000) Disease management C Bond (Eds) Evidence-based Pharmacy Pharmaceutical Press London 115–30
American Academy of Family Physicians. The FP Report. May 1996; 2(5)
Gurnee MC, Da Silva RV. Constructing Disease Management Programs. Managed Care 1997. http://www.managedcaremag.com/archives/9706/9706.disease_man.shtml
Anon (1999) Guide to Developing and Evaluating Medicine Education Programs and Materials for Children and Adolescents American School Health Association Kent OH
Fresle Wolfheim (1997) Public education on rational drug use: a global survey, WHO/DAP/97.5 WHO Geneva
M Drummond B Jönsson (2003) ArticleTitleMoving beyond the drug budget silo mentality in Europe Value Health 6 IssueIDSuppl 1 S74–7 Occurrence Handle10.1046/j.1524-4733.6.s1.8.x Occurrence Handle12846928
SB Soumerai D Ross-Degnan J Avorn T McLaughlin I Choodnovskiy (1991) ArticleTitleEffects of Medicaid drug-payment limits on admission to hospitals and nursing homes N Engl J Med 325 IssueID15 1072–7 Occurrence Handle1891009
S Schneeweiss M Maclure SB Soumerai AM Walker RJ. Glynn (2002) ArticleTitleQuasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance J Clin Epidemiol 55 833–41 Occurrence Handle10.1016/S0895-4356(02)00437-7 Occurrence Handle12384199
Schneeweiss S, Maclure M, Carleton B, Glynn RJ, Avorn J. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. BMJ, doi:10.1136/bmj.38020.698194.F6 (published 24 February 2004)
A Le Grand HV Hogerzeil FM Haaijer-Ruskamp (1999) ArticleTitleIntervention research in rational use of drugs: a review Health Policy plann 14 IssueID2 89–102 Occurrence Handle10.1093/heapol/14.2.89
AM Guillen L Cabiedes (2003) ArticleTitleReforming pharmaceutical policies in the European Union: a “Penguin Effect”? Int J Health Serv 33 IssueID1 1–28 Occurrence Handle10.2190/1JC6-FRL4-QM2L-QN6E Occurrence Handle12641260
TK Hazlet DK Blough (2002) ArticleTitleHealth services utilization with reference drug pricing of histamine(2) receptor antagonists in British Columbia elderly Med Care 40 IssueID8 640–9 Occurrence Handle10.1097/00005650-200208000-00003 Occurrence Handle12187178
D Nutbeam (1998) ArticleTitleEvaluating health promotion: progress, problems and solutions Health Promot Int 13 IssueID1 27–44 Occurrence Handle10.1093/heapro/13.1.27
DW Light T Walley (2004) A framework for containing costs fairly E Mossialos M Mrazek T Walley (Eds) Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality (European Observatory on Health Care Systems) Open University Press Maidenhead 346–58
N Daniels JE Sabin (2002) Setting Limits Fairly? Can We Learn to Share Medical Resources? Oxford University Press New York
Author information
Authors and Affiliations
Corresponding author
Additional information
* This article is the third in a series of articles on this topic that will appear in Pharmacy World & Science during 2005.
An erratum to this article can be found at http://dx.doi.org/10.1007/s11096-005-2497-z.
Rights and permissions
About this article
Cite this article
Almarsdóttir, A.B., Traulsen, J.M. Cost-Containment as Part of Pharmaceutical Policy. Pharm World Sci 27, 144–148 (2005). https://doi.org/10.1007/s11096-005-6953-6
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11096-005-6953-6